| |
wIRA group (n = 120)
|
Control group (n = 120)
|
Difference d
|
t-statistic
|
P value
|
95% CI
|
|---|
|
BASDAI
|
|
Before T*
|
8.33 ± 0.71
|
8.36 ± 0.74
|
− 0.04 ± 0.35
|
− 0.632
|
0.531
|
− 0.15~0.08
|
|
After T
|
7.65 ± 0.65
|
7.90 ± 0.62
|
− 0.26 ± 0.56
|
− 2.907
|
0.000
|
− 0.44~− 0.08
|
|
Difference d
|
0.68 ± 0.46
|
0.45 ± 0.49
|
–
|
0.35 ± 0.50
|
–
|
–
|
|
95% CI
|
0.53~0.83
|
0.30~0.61
|
–
|
0.24–0.47
|
–
|
–
|
|
P value
|
0.000
|
0.000
|
–
|
0.000
|
–
|
–
|
|
Pain VAS scores
|
|
Before T
|
8.85 ± 0.48
|
8.82 ± 0.45
|
0.03 ± 0.34
|
0.605
|
0.549
|
− 0.08~0.14
|
|
After T
|
7.30 ± 0.65
|
7.77 ± 0.46
|
− 0.46 ± 0.54
|
− 5.436
|
0.000
|
− 0.63~− 0.29
|
|
Difference d
|
1.55 ± 0.49
|
1.05 ± 0.35
|
–
|
0.27 ± 0.48
|
–
|
–
|
|
95% CI
|
1.39~1.70
|
0.94~1.16
|
–
|
0.16–0.37
|
–
|
–
|
|
P value
|
0.000
|
0.000
|
–
|
0.000
|
–
|
–
|
|
Morning stiffness VAS scores
|
|
Before T
|
8.81 ± 0.46
|
8.75 ± 0.50
|
0.06 ± 0.37
|
1.071
|
0.291
|
− 0.06~0.18
|
|
After T
|
7.26 ± 0.59
|
7.80 ± 0.55
|
− 0.54 ± 0.55
|
− 6.205
|
0.000
|
− 0.72~− 0.36
|
|
Difference d
|
1.55 ± 0.50
|
0.95 ± 0.35
|
–
|
0.28 ± 0.50
|
–
|
–
|
|
95% CI
|
1.38~1.71
|
0.83~1.06
|
–
|
0.17–0.39
|
–
|
–
|
|
P value
|
0.000
|
0.000
|
–
|
0.000
|
–
|
–
|
- T treatment, BASDAI bath ankylosing spondylitis disease activity index, VAS visual analogue scale, CI confidence interval
- *Before treatment: wIRA treatment (before the start of the first stage of treatment regimen A and before the start of the second stage of treatment regimen A); control group (before the start of the first stage of treatment regimen B and before the start of the second stage of treatment regimen A). After treatment: values before the corresponding treatment regimen and after the corresponding treatment regimen
